6-K: New Sarclisa Subcutaneous Formulation Met Co-Primary Endpoints in the IRAKLIA Phase 3 Study in Multiple Myeloma and Sarclisa Obtains First Approval in China for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

6-K：多發性骨髓瘤IRAKLIA 3期研究中新的Sarclisa皮下註射制劑達到共同主要終點，以及Sarclisa在中國首次獲批用於治療成人復發性或難治性多發性骨髓瘤患者